Ranbaxy Laboratories gets US FDA nod for Novartis' Diovan generic, set for $200 mn boost

Jun 28 2014, 15:20 IST
Comments 0
Ranbaxy Laboratories is in the process of being acquired by Sun Pharma for $3.2 billion. Ranbaxy Laboratories is in the process of being acquired by Sun Pharma for $3.2 billion.
SummaryRanbaxy Laboratories unit to manufacture, market Valsartan tablets on exclusive basis.

heartburn drug Nexium and Roche's antiviral Valcyte.

These two drugs are pending final approval from the FDA.

Last month, Ranbaxy Chief Executive Arun Sawhney said he was "confident" that the company would be able to reap the benefits of these exclusive marketing opportunities.

He did not elaborate.

"I think the Diovan generic approval is definitely a validation of their comment that they will be able to launch Valcyte and Nexium as well," Nirmal Bang's Bohra said.

Single Page Format
Ads by Google
Reader´s Comments
| Post a Comment
Please Wait while comments are loading...